FDA broadens APDS treatment options
An 8-patient study evaluated safety and pharmacokinetics in the younger pediatric population.
By
Kathryn Wighton
September 14, 2026
Clinical Scorecard: FDA broadens APDS treatment options
At a Glance
Category Detail
Condition Activated phosphoinositide 3-kinase delta syndrome (APDS) Key Mechanisms Mutations in PIK3CD or PIK3R1 impair immune system function. Target Population Pediatric patients aged 4 to 11 years weighing at least 27 kg. Care Setting Clinical treatment for rare genetic disorders.
Key Highlights
Leniolisib (Joenja) approved for younger pediatric patients. Efficacy demonstrated in reducing lymph node size and improving B-cell counts. Common adverse effects include abdominal pain and respiratory tract infections. Patients aged 4 to 11 receive weight-based doses of leniolisib. Leniolisib has orphan drug and rare pediatric disease designations. Guideline-Based Recommendations
Diagnosis
Confirm APDS-associated genetic mutations in patients. Management
Administer leniolisib orally twice daily at weight-based doses. Monitoring & Follow-up
Monitor for lymphoproliferation and immunophenotype normalization. Risks
Avoid use in patients with moderate to severe liver impairment. Patient & Prescribing Data
Pediatric patients aged 4 to 11 years with APDS.
Leniolisib is effective in managing symptoms and improving immune function.
Clinical Best Practices
Conduct genetic testing for APDS mutations. Monitor patients for adverse effects during treatment. Adjust dosing based on patient weight. Related Resources & Content
